Ewers Evan C, Sheffler Robert L, Wang James, Ngauy Viseth
Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Hematology/Oncology Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Gastroenterology Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Infectious Diseases Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii
Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Hematology/Oncology Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Gastroenterology Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Infectious Diseases Service, Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii.
Am J Trop Med Hyg. 2016 May 4;94(5):1177-81. doi: 10.4269/ajtmh.15-0831. Epub 2016 Feb 22.
Immunoproliferative small intestinal disease (IPSID) is an extra-nodal B-cell lymphoma most commonly described in the Mediterranean, Africa, and Asia. It is associated with poverty and poor sanitation, and is rarely encountered in developed countries. A 26-year-old previously healthy, Marshallese male was transferred to our facility with a 6-month history of watery diarrhea, weakness, and cachexia refractory to multiple short courses of oral antibiotics. Stool cultures grew Campylobacter jejuni and Vibrio fluvialis. Endoscopic evaluation showed histologic evidence of Helicobacter pylori gastritis and gross evidence of whipworm infection found in the colon. Mesenteric lymph node biopsy cultures grew Escherichia coli. Histopathology and immunohistochemical stains of the small intestine were consistent with IPSID. He subsequently transformed to diffuse large B-cell lymphoma (DLBCL) with tonsillar involvement despite treatment with rituximab and an extended course of antibiotics. Systemic chemotherapy with six cycles of rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone, and lenalidomide, resulted in remission of his diffuse B cell lymphoma. This case is illustrative of IPSID developing in a previously healthy individual due to overwhelming polymicrobial gastrointestinal infection by C. jejuni and other enteric pathogens with subsequent transformation to an aggressive DLBCL. IPSID should be considered in residents of developing countries presenting with refractory chronic diarrhea, weight loss, and mesenteric lymphadenopathy.
免疫增殖性小肠疾病(IPSID)是一种结外B细胞淋巴瘤,最常见于地中海地区、非洲和亚洲。它与贫困和卫生条件差有关,在发达国家很少见。一名26岁、此前健康的马绍尔群岛男性因水样腹泻、虚弱和恶病质病史6个月,经多次短期口服抗生素治疗无效后被转至我院。粪便培养物中培养出空肠弯曲菌和河流弧菌。内镜评估显示有幽门螺杆菌胃炎的组织学证据,以及在结肠中发现鞭虫感染的肉眼证据。肠系膜淋巴结活检培养物中培养出大肠杆菌。小肠的组织病理学和免疫组化染色与IPSID一致。尽管接受了利妥昔单抗治疗和延长疗程的抗生素治疗,但他随后仍转变为弥漫性大B细胞淋巴瘤(DLBCL)并累及扁桃体。使用利妥昔单抗、环磷酰胺、长春新碱、阿霉素、泼尼松和来那度胺进行六个周期的全身化疗,使他的弥漫性B细胞淋巴瘤得到缓解。该病例表明,IPSID可在一名此前健康的个体中因空肠弯曲菌和其他肠道病原体引起的压倒性多微生物胃肠道感染而发生,随后转变为侵袭性DLBCL。对于出现难治性慢性腹泻、体重减轻和肠系膜淋巴结病的发展中国家居民,应考虑IPSID。